An FDA deputy commissioner said the agency has not yet decided if the problems that led to withdrawal of Merck's Vioxx means the agency also should consider whether similar drugs are a concern. "We don't have any definitive evidence" the heart-risk problem that affected the Vioxx arthritis drug also is involved in other drugs in the Cox-2 class, Janet Woodcock said at a conference of arthritis specialists.

Related Summaries